AXQ Capital LP Sells 2,941 Shares of DaVita Inc. (NYSE:DVA)

AXQ Capital LP cut its holdings in shares of DaVita Inc. (NYSE:DVA) by 42.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,921 shares of the company’s stock after selling 2,941 shares during the quarter. AXQ Capital LP’s holdings in DaVita were worth $586,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. SBI Securities Co. Ltd. purchased a new position in DaVita in the 4th quarter worth approximately $41,000. Quarry LP bought a new stake in shares of DaVita during the third quarter valued at approximately $60,000. Venturi Wealth Management LLC lifted its holdings in shares of DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company’s stock worth $61,000 after buying an additional 152 shares in the last quarter. Versant Capital Management Inc boosted its position in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock worth $68,000 after acquiring an additional 169 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company’s stock valued at $76,000 after acquiring an additional 131 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on DVA. Barclays increased their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, StockNews.com downgraded DaVita from a “buy” rating to a “hold” rating in a research report on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $166.33.

DaVita Price Performance

NYSE:DVA opened at $148.25 on Friday. The firm has a market capitalization of $11.86 billion, a price-to-earnings ratio of 13.80, a PEG ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The business has a 50 day simple moving average of $158.53 and a 200-day simple moving average of $157.51. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.